SCOPE is testing administration of intramuscular SCIB1 and intradermal iSCIB1+, which codes for various melanoma antigens ...

The Cambridge, UK-headquartered company has said it will invest $50 billion in the US by 2030, with the centrepiece of its ...

The FDA appears to have won its staring contest with Sarepta over shipments of Elevidys, after the company blinked and agreed ...

Sanofi has moved to bolster its vaccines business by reaching a deal to buy London, UK-based biotech Vicebio, which was ...

Saultz and Lochner’s research have long highlighted how relational continuity enhances trust, communication, and shared ...

A once-daily tablet that can help people suffering from hay fever caused by birch tree pollen, Alk-Abelló's Itulazax, has ...

On day three of BIO 2025, editor-in-chief Jonah Comstock caught up with OS Therapeutics CEO Paul Romness and EVERSANA VP of ...

AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated ...

The FDA has a new director for the Center for Drug Evaluation and Research (CDER), with biopharma industry executive George ...

The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...